Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma

LONDON, October 14, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), IsoRay Inc. (NYSE MKT: ISR), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, October 13, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 16,321.07, down 1.35% and the NASDAQ Composite closed at 4,213.66, down 1.46%. The S&P 500 finished the session 1.65% lower at 1,874.74. During the trading session, all the ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 711.21, down 2.39%, whereas the index has advanced 10.73% on YTD basis. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

Gilead Sciences Inc.'s stock lost 2.21%, to close the day at $101.44. The stock recorded a trading volume of 14.53 million shares, above its three months average volume of 13.82 million shares. The company's shares oscillated between $101.36 and $104.57 during the session. Over the last three trading sessions and over the past one month, Gilead Sciences Inc.'s shares have fallen by 6.82% and 2.14%, respectively. However, the stock has gained 35.07% since the start of this year. The stock is trading above its 200-day moving average of $85.50, which is below the 50-day moving average of $103.03. Additionally, the stock traded at a PE ratio of 22.46 and has a Relative Strength Index (RSI) of 46.91. Sign up and read the free notes on GILD at:

www.Investor-Edge.com/GILD-14Oct2014

On Monday, shares in MannKind Corp. recorded a trading volume of 6.49 million shares, lower than its three months average volume of 7.96 million shares. The stock ended the day at $4.61, which was 1.50% below its previous day's closing of $4.68, and registered an intraday range of $4.45 and $4.80. MannKind Corp.'s stock has lost 11.18% in the previous three trading sessions, 30.99% in the last one month, and 11.35% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $6.76 and $7.09, respectively. Furthermore, shares of MannKind Corp. have an RSI of 13.03. The complimentary notes on MNKD can be downloaded as in PDF format at:

www.Investor-Edge.com/MNKD-14Oct2014

IsoRay Inc.'s stock plummeted 6.25% to end Monday's session at $1.35. The stock recorded a trading volume of 0.65 million shares, below its three months average volume of 1.08 million shares. The company's shares fluctuated between $1.33 and $1.45 during the session. IsoRay Inc.'s shares have rallied 170.00% since the beginning of 2014. However, the stock has declined 12.90% over the previous three trading sessions and 44.44% in the last one month. The stock is trading below its 50-day and 200-day moving averages. IsoRay Inc.'s shares 50-day moving average of $2.20 is above its 200-day moving average of $1.96. Additionally, the stock has an RSI of 29.14. Register for free on Investor-Edge and access the latest research on ISR at:

www.Investor-Edge.com/ISR-14Oct2014

On Monday, shares in Orexigen Therapeutics Inc. ended the session 4.66% lower at $3.27, hitting a new 52-week low $3.11. The stock reported a trading volume of 3.65 million shares, lower than its three months average volume of 3.88 million shares. Orexigen Therapeutics Inc.'s shares have declined 10.90% in the previous three trading sessions, 36.63% in the last one month, and 41.92% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $5.08 and $5.88, respectively. Moreover, shares of Orexigen Therapeutics Inc. have an RSI of 16.55. The complete research on OREX is available for free at:

www.Investor-Edge.com/OREX-14Oct2014

Sunesis Pharmaceuticals Inc.'s stock finished Monday's session 0.95% higher at $1.06, after hitting a new 52-week low of $1.00. A total of 1.66 million shares were traded, which was below its three months average volume of 1.82 million shares. The stock vacillated between $1.00 and $1.13 during the session. Over the last one month and over the previous three months, Sunesis Pharmaceuticals Inc.'s shares have plummeted 85.50% and 82.30%, respectively. Additionally, from the beginning of 2014, the stock has declined 77.64%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $6.59 is greater than its 200-day moving average of $5.86. Sunesis Pharmaceuticals Inc.'s stock has an RSI of 13.17. Free in depth research on SNSS is available at:

www.Investor-Edge.com/SNSS-14Oct2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED